PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle mass alongside GLP-1 therapies. This emerging category is gaining industry attention due to its potential to enhance body composition and patient results, supported by strategic acquisitions like Eli Lilly's purchase of Versanis Bio. The report suggests muscle-preservation therapies will complement rather than replace GLP-1 drugs, creating new opportunities in pharmaceutical partnerships, licensing, and intellectual property. This marks a shift in obesity treatment focus from just weight loss to improving the quality of weight loss over time.
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
Eli Lilly announced it will file for regulatory approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027 after successful late-stage trials. The drug showed significant weight loss—up to 22.6% of body weight—and improve...
